Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN17235 in CCUS and LR-MDS with SF3B1 Mutation
NCT07753148Phase 1Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- May 2031
- Countries
- 1
01
Overview
Phase 1, open-label trial of REGN17235 in clonal cytopenia of undetermined significance (CCUS) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Occurrence of Treatment Emergent Adverse Events at 5 years, Severity of Treatment Emergent Adverse Events at 5 years and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
REGN17235
03
Conditions
clonal cytopenia of undetermined significance (CCUS)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07753148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07753148.